EFFICACY OF PIOGLITAZONE APPLICATION IN COMPLEX TREATMENT OF PSORIASIS PATIENTS WITH ACCOMPANYING ALIMENTARY OBESITY
About the author:	Ya.A. Emchenko, K.E. Ischejkin, I.P. Kaidashev	
Heading	CLINICAL OBSERVATIONS	
Type of article	Scientific Article	
Annotation	Relevance. Psoriasis is the common chronic genetically determined autoimmune polyetiological inflammatory disease with impaired
epidermal proliferation, provoked by exogenous and endogenous factors, and manifested by erythematous and scaly elements, papules and plaques. Despite the significant prevalence of psoriasis and a large number of studies on this problem, there is still no single view on the pathogenesis of this dermatosis. To objectively understand the pathogenesis of psoriasis, it is necessary to take into account the insufficiently studied comorbidity of this pathology. Recently, an indisputable link between psoriasis and obesity has been proven. The scientific literature widely covers the issue of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity. Given the current data on the role of systemic inflammation underlying the development of both psoriasis and obesity, the study of molecular mechanisms of its development and taking into account the role of proinflammatory nuclear transcription factors, thiazolidinediones are the pathogenetically justified drugs of choice for treatment of these diseases. The objective. To determine the effectiveness of the use of 45 mg of pioglitazone 1 time per day for 26 weeks in the complex treatment of patients with widespread psoriasis vulgaris of moderate severity with concomitant alimentary obesity of I–II degrees. Materials and research methods. Clinical and immunological studies of indicators of systemic inflammation.
Results. the use of 45 mg pioglitazone for 26 weeks led to a decrease in systemic inflammation in terms of IL-33 by 83.7%, IL-6 by 72%, uch-CRP by 76.8% and the PASI index by 46.8% with repeated relapse diseases.
Conclusions. Long-term use of 45 mg of pioglitazone in the complex treatment of patients with widespread psoriasis vulgaris of moderate severity with concomitant alimentary obesity of I–II degrees proved to be effective and contributed to a milder course of psoriasis with repeated relapse of the disease.	
Tags	psoriasis, alimentary obesity, systemic inflammation, treatment	
Bibliography	1. Yemchenko Ya. Riven pokaznykiv systemnoho zapalennia u khvorykh na psoriaz obtiazhenyi metabolichnym syndromom (The level of systemic inflammation in patients with psoriasis is burdened by metabolic syndrome). Zhurnal dermatovenerolohii ta kosmetolohii imeni M.O. Torsueva. 
2018;1(38):31–35 [in Ukrainian].
2. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii. Ukraїns’kiy medichniy chasopis (Nf‑kb signaling as a basis for the development of systemic inflammation, insulin resistance, lipotoxic‑
ity, type 2 diabetes mellitus and atherosclerosis). 2013;5:103–108 [in Ukrainian].
3. Kaydashev IP. NF‑kB‑signalizaciya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2‑go tipa i ateroskleroza (Nf‑kb signaling as a basis for the development of systemic inflammation, insulin resistance, lipotoxicity, type 2 diabetes mellitus 
and atherosclerosis). Mezhdunarodnyy endokrinologicheskiy zhurnal. 2013;3(35):35–40 (Ukrainian).
4. Rasin MS, Rasin SM. Faktory transkripcii v centre sovremennoj biologii i mediciny (Transcription factors in the center of modern biology and medicine. Receptors activated by peroxisome proliferators). 
Receptory, aktiviruemye proliferatorami peroksisom. Likarska sprava. 2013;3:280–285.
5. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity Int J Pediat Obes. 2018;3(1):37–43.
6. Bertheloot D, Latz E. HMGB1, IL‑1a, IL‑33 and S100 proteins: dualfunction alarmins. Cell Mol Immunol. 2017;14(1):43–64.
7. Brikos C, O´Neill LA.Signaling of toll‑like receptors. Handb Exp Pharmacol. 2018;183:21–50.
8.  Clark  RA.  Resident  memory  T  cells  in  human  health  and  disease.  Sci  Transl  Med. 2015;7(269):269–274.
9. Cosmi L, Liotta F, Maggi E. Th17 and non‑classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol. 2014;164(3):171–177.
10. Fredriksson T, Pettersson U. Severe psoriasis –  oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–44. PMID357213.
11. Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M. Serum IL‑33 levels are increased in patients with psoriasis. Experimental dermatology. 2015;3(2):234–239.
12. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 00–4084.
13. Suganami T, Tanimoto‑Koyama K, Nishida J, et al. Role of the Tolllike receptor 4/NF‑kappaB pathway in saturated fatty acid‑induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2017;27:84–91.
14. Schernthaner G, Craig Currie J, Schernthaner G. Do we still need pioglitazone for the treatment of type 2 diabetes. A risk‑benefit critique in 2013. Diabetes Care. 2013;36:2013–2031.
15. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. Psoriasis –  as an autoimmune disease caused by molecular mimicry. Trends Immunol. 2015;30(10):494–501.
16. Zhao W, Wu C, Li S, Chen X. Adiponectin protects palmitic acid induced endothelial inflam‑mation and insulin resistance via regulating ROS/IKKβ pathways. Cytokine. 2016;88:167–176.	
Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №4(90), 2020 year, 22-25 pages,
 index UDK   616.515–056.52:615.262	
DOI	10.33743/2308-1066-2020-4-22-25